Journal of International Psychiatry

[Abstracts]Purposes Explore the changes of AD patient’s psychiatric symptoms and cognitive functions after Piracetam and Rivastigmine interventions. Methods From 6-2013 to 1-2016 in our hospital from 100 cases of AD patients were randomly divided into observation group and control group; the control group were treated with Piracetam Tablets, the observation group were treated with piracetam combined with Rivastigmine treatment; to evaluate the clinical curative effect of the treatment of 6 months; using the PANSS scale, BEHAVE-AD, Blessed-Roth behavior scale of spirit the symptoms of patients were evaluated before and after treatment, the use of MMSE scale and GDS scale were used to evaluate the cognitive function of patients with adverse reactions, questionnaire were used to investigate the use of TESS. Results The observation group of patients with clinical efficiency was significantly higher than the control group (P<0.05); the two groups after treatment in patients with PANSS, BEHAVE-AD, Blessed-Roth scores were significantly improved (P<0.05), and the observation group three scale score improvement was significantly higher than the control group (P<0.05); the MMSE of two groups after treatment, GDS scores were significantly improved (P<0.05), and the observation group MMSE, GDS score improvement was significantly higher than the control group (P<0.05); observation group of patients with irritable clinical incidence was significantly lower than the control group (P<0.05). Conclusions The combination of Piracetam and Rivastigmine can significantly improve cognitive function and psychiatric symptoms in patients with AD, and it has higher safety.

[Keywords] Piracetam; Rivastigmine; Alzheimers Disease; Psychiatric Symptoms; Cognitive Function